170 related articles for article (PubMed ID: 33054843)
1. Diagnostic value of clusterin immunostaining in hepatocellular carcinoma.
Li Y; Liu F; Zhou W; Zhang S; Chu P; Lin F; Wang HL
Diagn Pathol; 2020 Oct; 15(1):127. PubMed ID: 33054843
[TBL] [Abstract][Full Text] [Related]
2. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytology.
Saad RS; Luckasevic TM; Noga CM; Johnson DR; Silverman JF; Liu YL
Diagn Cytopathol; 2004 Jan; 30(1):1-6. PubMed ID: 14696137
[TBL] [Abstract][Full Text] [Related]
4. pCEA canalicular immunostaining in fine needle aspiration biopsy diagnosis of hepatocellular carcinoma.
Wee A; Nilsson B
Acta Cytol; 1997; 41(4):1147-55. PubMed ID: 9250313
[TBL] [Abstract][Full Text] [Related]
5. The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma.
Karabork A; Kaygusuz G; Ekinci C
Pathol Res Pract; 2010 Aug; 206(8):572-7. PubMed ID: 20400233
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical stains of proliferating cell nuclear antigen, insulin-like growth factor 2 and clusterin help distinguish malignant from benign liver nodular lesions.
Lai JP; Chen ZM; Lok T; Chan OT; Himmelfarb E; Zhai Q; Lin F; Wang HL
J Clin Pathol; 2014 Jun; 67(6):464-9. PubMed ID: 24407433
[TBL] [Abstract][Full Text] [Related]
7. Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas.
Borscheri N; Roessner A; Röcken C
Am J Surg Pathol; 2001 Oct; 25(10):1297-303. PubMed ID: 11688465
[TBL] [Abstract][Full Text] [Related]
8. HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates.
Wang L; Vuolo M; Suhrland MJ; Schlesinger K
Acta Cytol; 2006; 50(3):257-62. PubMed ID: 16780018
[TBL] [Abstract][Full Text] [Related]
9. Clusterin plays an important role in hepatocellular carcinoma metastasis.
Lau SH; Sham JS; Xie D; Tzang CH; Tang D; Ma N; Hu L; Wang Y; Wen JM; Xiao G; Zhang WM; Lau GK; Yang M; Guan XY
Oncogene; 2006 Feb; 25(8):1242-50. PubMed ID: 16247463
[TBL] [Abstract][Full Text] [Related]
10. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.
Cai MY; Tong ZT; Zheng F; Liao YJ; Wang Y; Rao HL; Chen YC; Wu QL; Liu YH; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
Gut; 2011 Jul; 60(7):967-76. PubMed ID: 21330577
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of clusterin in hepatocellular carcinoma: A meta-analysis.
Gao G; Luan X
Int J Biol Markers; 2022 Dec; 37(4):404-411. PubMed ID: 35645149
[TBL] [Abstract][Full Text] [Related]
12. Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma.
Röcken C; Licht J; Roessner A; Carl-McGrath S
J Clin Pathol; 2005 Oct; 58(10):1069-75. PubMed ID: 16189153
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of CD10 in differentiating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration biopsy (FNAB) of the liver.
Lin F; Abdallah H; Meschter S
Diagn Cytopathol; 2004 Feb; 30(2):92-7. PubMed ID: 14755758
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic utility of immunohistochemistry in hepatocellular carcinoma, its variants and their mimics.
Wee A
Appl Immunohistochem Mol Morphol; 2006 Sep; 14(3):266-72. PubMed ID: 16932016
[TBL] [Abstract][Full Text] [Related]
15. cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma.
Xiao SY; Wang HL; Hart J; Fleming D; Beard MR
Am J Pathol; 2001 Oct; 159(4):1415-21. PubMed ID: 11583969
[TBL] [Abstract][Full Text] [Related]
16. The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma.
Patarat R; Riku S; Kunadirek P; Chuaypen N; Tangkijvanich P; Mutirangura A; Puttipanyalears C
Sci Rep; 2021 Jul; 11(1):14838. PubMed ID: 34290294
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of CD10 immunohistochemical staining on cellblock in differentiating hepatocellular carcinoma from secondary malignancies of liver.
Singha J; Khan K; Chatterjee S
Indian J Pathol Microbiol; 2018; 61(4):510-515. PubMed ID: 30303139
[TBL] [Abstract][Full Text] [Related]
18. Bile salt export pump: a sensitive and specific immunohistochemical marker of hepatocellular carcinoma.
Lagana SM; Salomao M; Remotti HE; Knisely AS; Moreira RK
Histopathology; 2015 Mar; 66(4):598-602. PubMed ID: 25378077
[TBL] [Abstract][Full Text] [Related]
19. Role of CD10 immunochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver.
Ahuja A; Gupta N; Kalra N; Srinivasan R; Chawla Y; Rajwanshi A
Cytopathology; 2008 Aug; 19(4):229-35. PubMed ID: 18070122
[TBL] [Abstract][Full Text] [Related]
20. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
Lee MH; Kim SH; Park MJ; Park CK; Rhim H
AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
